Last reviewed · How we verify
VC005 high dose group
VC005 high dose group is a SGLT2 inhibitor Small molecule drug developed by Jiangsu vcare pharmaceutical technology co., LTD. It is currently in Phase 3 development for Type 2 diabetes.
VC005 is a small molecule that targets the SGLT2 receptor.
VC005 is a vaccine component that induces an immune response, as indicated by its mechanism of action. It is being studied in a Phase III clinical trial for its efficacy and safety in treating Active Ankylosing Spondylitis, Moderate to Severe Atopic Dermatitis, and Atopic Dermatitis.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | VC005 high dose group |
|---|---|
| Sponsor | Jiangsu vcare pharmaceutical technology co., LTD |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, VC005 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo (PHASE2)
- Efficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis. (PHASE3)
- Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate Atopic Dermatitis (PHASE2)
- Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis (PHASE3)
- Safety, Tolerance and Pharmacokinetics Clinical Study of VC005 in Healthy Subjects and Patients with Mild to Moderate Atopic Dermatitis (PHASE1)
- Efficacy and Safety Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis. (PHASE2)
- Efficacy and Safety Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis (PHASE2)
- A Phase I Clinical Study of VC005 Tablets in Subjects With Rheumatoid Arthritis. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VC005 high dose group CI brief — competitive landscape report
- VC005 high dose group updates RSS · CI watch RSS
- Jiangsu vcare pharmaceutical technology co., LTD portfolio CI
Frequently asked questions about VC005 high dose group
What is VC005 high dose group?
How does VC005 high dose group work?
What is VC005 high dose group used for?
Who makes VC005 high dose group?
What drug class is VC005 high dose group in?
What development phase is VC005 high dose group in?
What are the side effects of VC005 high dose group?
What does VC005 high dose group target?
Related
- Drug class: All SGLT2 inhibitor drugs
- Target: All drugs targeting SGLT2
- Manufacturer: Jiangsu vcare pharmaceutical technology co., LTD — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing